X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES GSK PHARMA VENUS REMEDIES/
GSK PHARMA
 
P/E (TTM) x -845.0 64.6 - View Chart
P/BV x 0.2 10.4 2.4% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 VENUS REMEDIES   GSK PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
GSK PHARMA
Mar-17
VENUS REMEDIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs2183,838 5.7%   
Low Rs822,637 3.1%   
Sales per share (Unadj.) Rs365.6354.2 103.2%  
Earnings per share (Unadj.) Rs1.539.8 3.7%  
Cash flow per share (Unadj.) Rs37.942.9 88.5%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs382.5236.9 161.5%  
Shares outstanding (eoy) m11.4484.70 13.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.49.1 4.5%   
Avg P/E ratio x101.081.4 124.0%  
P/CF ratio (eoy) x4.075.5 5.2%  
Price / Book Value ratio x0.413.7 2.9%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m1,717274,216 0.6%   
No. of employees `0001.04.7 21.7%   
Total wages/salary Rs m3244,830 6.7%   
Avg. sales/employee Rs Th4,100.76,387.0 64.2%   
Avg. wages/employee Rs Th318.01,028.3 30.9%   
Avg. net profit/employee Rs Th16.7717.1 2.3%   
INCOME DATA
Net Sales Rs m4,18330,000 13.9%  
Other income Rs m20728 2.8%   
Total revenues Rs m4,20330,728 13.7%   
Gross profit Rs m8124,190 19.4%  
Depreciation Rs m417263 158.5%   
Interest Rs m3800-   
Profit before tax Rs m354,655 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m181,744 1.0%   
Profit after tax Rs m173,368 0.5%  
Gross profit margin %19.414.0 138.9%  
Effective tax rate %51.637.5 137.6%   
Net profit margin %0.411.2 3.6%  
BALANCE SHEET DATA
Current assets Rs m2,77116,742 16.5%   
Current liabilities Rs m1,9317,202 26.8%   
Net working cap to sales %20.131.8 63.1%  
Current ratio x1.42.3 61.7%  
Inventory Days Days12552 241.4%  
Debtors Days Days5421 258.6%  
Net fixed assets Rs m5,3288,635 61.7%   
Share capital Rs m114847 13.5%   
"Free" reserves Rs m4,17719,222 21.7%   
Net worth Rs m4,37620,069 21.8%   
Long term debt Rs m1,91110 19,105.0%   
Total assets Rs m8,42830,038 28.1%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40 87,611.7%  
Sales to assets ratio x0.51.0 49.7%   
Return on assets %4.711.2 42.0%  
Return on equity %0.416.8 2.3%  
Return on capital %6.625.5 25.9%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m0528 0.0%   
Fx outflow Rs m8587,193 11.9%   
Net fx Rs m-858-6,665 12.9%   
CASH FLOW
From Operations Rs m4692,360 19.9%  
From Investments Rs m293,008 1.0%  
From Financial Activity Rs m-464-5,108 9.1%  
Net Cashflow Rs m35260 13.3%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 1.8%  
FIIs % 0.6 23.8 2.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 15.4 431.2%  
Shareholders   20,121 102,036 19.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS